{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T09:21:20Z","timestamp":1724577680662},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/mph.0000000000000453","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T14:39:51Z","timestamp":1446302391000},"page":"70-73","source":"Crossref","is-referenced-by-count":6,"title":["JAK2+ Essential Thrombocythemia in a Young Girl With Budd-Chiari Syndrome"],"prefix":"10.1097","volume":"38","author":[{"given":"Julie C.","family":"Wigton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M.","family":"Tersak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-15-20210209","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-2-3","article-title":"Essential thrombocythemia.","volume":"2","author":"Briere","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"R2-15-20210209","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":". Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"key":"R3-15-20210209","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":". Chronic health conditions in adult survivors of childhood cancer.","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-15-20210209","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05329.x","article-title":"Primary and secondary thrombocytosis in childhood.","volume":"129","author":"Dame","year":"2005","journal-title":"Br J Haematol"},{"key":"R5-15-20210209","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2006-04-014746","article-title":". Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.","volume":"108","author":"Randi","year":"2006","journal-title":"Blood"},{"key":"R6-15-20210209","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/bjh.12530","article-title":"Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.","volume":"163","author":"Fu","year":"2013","journal-title":"Br J Haematol"},{"key":"R7-15-20210209","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The Revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal.","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"key":"R9-15-20210209","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bcmd.2005.12.031","article-title":"Thrombotic complications in essential thrombocythemia (ET): clinical facts and biochemical riddles.","volume":"36","author":"Petrides","year":"2006","journal-title":"Blood Cells Mol Dis"},{"key":"R10-15-20210209","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":". Anagrelide Study Group. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk Res"},{"key":"R11-15-20210209","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","article-title":"Long-term use of anagrelide in young patients with essential thrombocythemia.","volume":"97","author":"Storen","year":"2001","journal-title":"Blood"},{"key":"R12-15-20210209","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":". Hydroxyurea for sickle cell disease: a systemic review for efficacy and toxicity in children.","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"key":"R13-15-20210209","first-page":"1550","article-title":". Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS Study, a phase III trial.","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"key":"R15-15-20210209","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":". Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"key":"R16-15-20210209","first-page":"141","article-title":"Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated Best Pract Res Clin Haematol.","volume":"27","author":"Bjorkholm","year":"2014","journal-title":""},{"key":"R17-15-20210209","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":". Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"R18-15-20210209","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":". ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial.","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"R19-15-20210209","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ajh.23217","article-title":". Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined earlyprefibrotic myelofibrosis: an international study of 264 patients.","volume":"87","author":"Buxhofer-Ausch","year":"2012","journal-title":"Am J Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000000453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:47:38Z","timestamp":1620964058000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201601000-00015"}},"subtitle":["Diagnostic and Therapeutic Considerations When Adult Disease Strikes the Young"],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000000453","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}